June 13 , 2013
Helix BioPharma Corp. announces appointment of director
Helix BioPharma Corporation Helix BioPharma Corporation is a biopharmaceutical company mainly focused in the field of cancer therapy. The Company is actively developing products for the treatment and prevention of cancer based on its proprietary technologies. The Company’s product development initiatives have focused primarily on its L-DOS47 and Topical Interferon Alpha-2b clinical-stage, new drug candidates. L-DOS47 is designed for the treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC), based on Helix’s patented platform technology, DOS47. Topical Interferon Alpha-2b is based on Helix’s patented Biphasix™ platform technology, and is designed to treat epidermal lesions. In particular, Helix has focused on developing the product for the treatment of potentially precancerous, low-grade cervical lesions caused by human papillomavirus (HPV) infections. The Company believes that its growth and future prospects are largely dependent on the success of at least one of the Company’s drug product candidates.
Helix is headquartered in Toronto, Canada and listed on the Toronto Stock Exchange (TSX) and Frankfurt Stock Exchange (FSE) under the symbol: HBP.
Topical Interferon Alpha-2b
Background and Phase II Program Click here for more information.
L-DOS47
What is L-DOS47? Learn more about Helix's potential cancer therapeutic. Click Here for more information.
